Safety, Tolerability and Patient Evaluation of Peginterferon beta-1a Administered Via a Single-Use Autoinjector in Relapsing Multiple Sclerosis: Data from the Phase 3 ATTAIN Study (P01.167)

CONCLUSIONS: Results will help to establish the safety and tolerability profiles of peginterferon beta-1a administered via autoinjector in MS patients, and evaluate patient perceptions of the injection process using the autoinjector.Supported by: Biogen Idec Inc.Disclosure: Dr. Calabresi has received personal compensation for activities with Biogen Idec, Teva Neuroscience, Genzyme Corporation, Vaccinex, Vertex, and Novartis. Dr. Calabresi has received research support from the National Institutes of Health, the National Multiple Sclerosis Society, Nancy Davis Foundation, Biogen Idec, Vertex, Genentech, Inc., Abbott, and Bayer. Dr. Liu has received personal compensation for activities with Biogen Idec as an employee. Dr. Liu holds stock and/or stock options in Biogen Idec. Dr. Seddighzadeh has received personal compensation for activities with Biogen Idec as an employee. Dr. Seddighzadeh holds stock in Biogen Idec, which sponsored research in which Dr. Seddighzadeh was involved as an investigator. Dr. Seddighzadeh holds stock in Biogen Idec. Dr. Sperling has received personal compensation for activities with Biogen Idec as an employee. Dr. Sperling hold stock and/or stock options in Biogen Idec. Dr Hung has received personal compensation for activities with Biogen Idec as an employee. Dr. Hung holds stock and/or stock options in Biogen Idec. Dr. Deykin has received personal compensation for activities with Biogen Idec as an employee. Dr. Deykin holds stock and/or stock options...

Source: Neurology - February 14, 2013 Category: Neurology Authors: Calabresi, P., Liu, S., Seddighzadeh, A., Sperling, B., Hung, S., Deykin, A. Tags: P01 Multiple Sclerosis: Treatment Safety Source Type: research